Maintenance Therapy Duration and Considerations for Treatment Interruption

Data from the SunRISe-4 trial demonstrate the benefit of adding TAR-200 to checkpoint inhibition among patients with muscle-invasive bladder cancer.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Durvalumab improved efficacy in patients with muscle-invasive bladder cancer.

Cancer Network spoke with Dr. Petros Grivas about emerging immunotherapy approaches for the treatment of advanced urothelial cancer.

Patient-reported outcomes from the EV-302 trial found consistent efficacy and safety outcomes for patients with urothelial carcinoma.

Limited efficacy was observed when sacituzumab govitecan was given after enfortumab vedodin in metastatic urothelial carcinoma.